Clinical Trials Logo

Chikungunya Virus Infection clinical trials

View clinical trials related to Chikungunya Virus Infection.

Filter by:

NCT ID: NCT06106581 Recruiting - Clinical trials for Chikungunya Virus Infection

A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years

Start date: December 18, 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control. At least 300 male and female healthy children aged 1 to 11 years will be enrolled and the overall distribution of participants will be 2:2:1 to the two VLA1553 dose groups (n=120 each) or control (n=60).

NCT ID: NCT06028841 Recruiting - Clinical trials for Chikungunya Virus Infection

A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)

Start date: April 10, 2024
Phase: Phase 3
Study type: Interventional

This is a phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of VLA1553 in moderately immunocompromised adults with HIV infection.

NCT ID: NCT06007183 Recruiting - Clinical trials for Chikungunya Virus Infection

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Start date: August 30, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of PXVX0317 in adult and adolescent participants and to evaluate PXVX0317 booster vaccine induced serum neutralizing antibody (SNA) response at 3, 4, or 5 years post-initial PXVX0317 vaccination.

NCT ID: NCT04909411 Completed - Clinical trials for Chikungunya Virus Infection

Consequences of a Maternal-fetal Chikungunya Virus Infection

CHIK13+
Start date: January 13, 2020
Phase: N/A
Study type: Interventional

Chikungunya is an infectious disease caused by an alphavirus transmitted by the Aedes mosquitoes which has known a worldwide expansion since its re-emergence in 2004. Regarding to an unprecedented epidemic, Reunionese pediatricians described in 2005-2006 a vertical maternal-fetal transmission of this virus, at the time of childbirth. Since then, this mode of transmission has been widely confirmed, with an absolute risk estimated between 15.5% and 48.3%. The main consequences for the child are neuromotor, neurosensory or neurocognitive. They were studied around the age of 2 in 33 children in the CHIMERE cohort, as well as at the age of 5 in a small fraction of these children followed at the C.A.M.S.P (Center for Early Medico-Social Action). The results suggested an overall delay in psychomotor acquisitions secondary to neonatal infection, affecting the functions of the prefrontal region (in particular coordination and language). Performance was correlated with the severity of the clinical presentation (more severe in case of encephalitis or encephalopathy) while remaining suboptimal in children with uncomplicated infection. During neurodevelopmental monitoring, other disturbing traits complemented the spectrum of problems presented by these children, such as microcephaly, cerebral palsy, epilepsy, interaction disorder or attention deficit disorder. At around age 10, the investigators reassessed 21 of these children using the Childhood Cognitive Function and Learning (EDA) screening test. The investigators would now like to confirm and characterize their impairments using a battery of confirmatory tests around the age of 13.

NCT ID: NCT04838444 Active, not recruiting - Clinical trials for Chikungunya Virus Infection

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)

Start date: April 2, 2021
Phase: Phase 3
Study type: Interventional

In this open-label Phase 3b, single arm study, persistence of antibodies and long term safety will be evaluated in up to 375 subjects rolled over from study VLA1553-301 (NCT number: NCT04546724).

NCT ID: NCT04786444 Completed - Clinical trials for Chikungunya Virus Infection

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

Start date: February 22, 2021
Phase: Phase 3
Study type: Interventional

This was a prospective, randomized, double-blinded, multicenter Phase 3 clinical study investigating three Lots of VLA1553 at the final dose. Overall 409 healthy subjects aged 18 to 45 years were randomized into the study.

NCT ID: NCT04546724 Completed - Clinical trials for Chikungunya Virus Infection

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

Start date: September 17, 2020
Phase: Phase 3
Study type: Interventional

This was a prospective, randomized, double-blinded, multicenter, pivotal clinical study evaluating the final dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The final dose of VLA1553 or control was administered as single immunization on Day 1. Overall, 4.128 male and female subjects aged 18 years and above were randomized into the study.

NCT ID: NCT04455919 Terminated - Clinical trials for Chikungunya Virus Infection

Yoga for Chronic Chikungunya

YOCHIK
Start date: October 3, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the benefits of a 8-week yoga program on quality of life in patients suffering from chronic chikungunya. Studies have already shown the effectiveness of yoga practice on various arthralgia's, on the reduction of inflammatory reactions, on psychological disorders/sleep disorders and on quality of life. Considering quality of life as a global experience of balance between physical and mental wellbeing, the hypothesis was that the practice of yoga would globally improve the quality of life of patients with chronic chikungunya.

NCT ID: NCT04441905 Active, not recruiting - Clinical trials for Chikungunya Virus Infection

Phase 1 Study of SAR440894 vs Placebo

Start date: October 14, 2020
Phase: Phase 1
Study type: Interventional

A single, ascending-dose design with five dose-cohorts of 8 subjects. Forty healthy adults aged 18 to 45, inclusive, will be recruited and admitted at multiple sites. Each subject will be randomized to receive either SAR440894 or matching placebo via 60-minute intravenous infusion. In each cohort of 8 subjects, the randomization ratio will be 6 active to 2 placebo, and 2 sentinel subjects (one from each active and placebo group) will be dosed first. Dosing of the next dose-cohort will be dependent on acceptable meeting predefined safety criteria in the preceding cohort. Each subject's participation will take place over approximately 150 days, not including the screening visit. There are no hypotheses for this phase I study. The primary objective will be to determine the safety of single ascending intravenous (IV) infusions of SAR440894 when administered in healthy adults.

NCT ID: NCT03807843 Completed - Clinical trials for Chikungunya Virus Infection

Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)

Start date: July 16, 2019
Phase: Phase 2
Study type: Interventional

Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection. Initially 21 to 50 year old participants will be enrolled; after favorable review of safety data, participants aged 51 to 65 will be enrolled.